Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- CMCM +12.3%, YRD +4.2%, SMG +1%
M&A news:
- NUTR +49.8% ( to be acquired by private-equity firm HGGC for $41.80/share)
- HUN +7.6% (Huntsman and Clariant (CLZNY) to combine in merger of equals with $20 bln enterprise value)
- AEG +2.4% (to divest its two largest US run-off businesses)
Other news:
- BIOC +21% (awarded a U.S. patent for the broad use of antibodies for the capture of any target of interest on any solid surface from any sample type)
- RDUS +15.6% (benefiting from AMGN's announcement that cardiovascular adverse events were observed as a new safety signal in patients in Phase 3 EVENITY data)
- CRMD +6.1% (CEO disclosed purchase of 75000 shares worth $36K)
- BLRX +5.9% (announces filing of regulatory submissions required to commence a Phase 1b trial for BL-8040)
- GNC +5.1% (in sympathy with NUTR)
- BX +5.1% (confirmed it will launch $40 bln infrastructure investment vehicle and new infrastructure business)
- MYOV +4.6% (presentation of 'positive' Phase 2 data for Relugolix)
- MOMO +3.6% (continued strength)
- LMT +3% (LMT and Kingdom of Saudi Arabia sign MOU build defense capabilities in the KSA through 2030)
- RTN +2.7% (RTN and the Saudi Arabia Military Industries Company signed a Memorandum of Understanding)
- ZTO +2.5% (authorizes $300 mln share repurchase program)
- F +2.1% (reports of plans to replace its CEO Mark Fields, according to NY Times; will host a news conference at 9:45 ET today)
- VRX +1% (launches renu Advanced Formula multi-purpose solution for soft and silicone hydrogel contact lenses)
Analyst comments:
- NTNX +9.6% (upgraded to Buy from Neutral at Goldman)
- AAOI +3.8% (initiated with a Strong Buy at Needham)
- CREE +3.1% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities)
- QCOM +1.7% (upgraded to Overweight from Neutral at JP Morgan)
- MYL +1.2% (upgraded to Overweight from Equal Weight at Barclays)